A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 286 (planned)
- Started
- Feb 17, 2025
- Main results expected
- Jan 4, 2029
- Fully finished
- Jan 5, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)
Measured over: Up to 135 days post last treatment visit
Number of participants with Serious AEs (SAEs) as assessed by NCI-CTCAE v5.0
Measured over: Up to 135 days post last treatment visit
Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria as assessed by NCI-CTCAE v5.0
Measured over: Up to Day 28
Number of participants with AEs leading to discontinuation as assessed by NCI-CTCAE v5.0
Measured over: Up to 135 days post last treatment visit
Number of deaths as assessed by NCI-CTCAE v5.0
Measured over: Through study completion (Up to 4 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06697197 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC